KR102155246B1 - Composition for improving skin conditions comprising Dendropanax Morbifera extracts-metal nanoparticles complex - Google Patents
Composition for improving skin conditions comprising Dendropanax Morbifera extracts-metal nanoparticles complex Download PDFInfo
- Publication number
- KR102155246B1 KR102155246B1 KR1020170099113A KR20170099113A KR102155246B1 KR 102155246 B1 KR102155246 B1 KR 102155246B1 KR 1020170099113 A KR1020170099113 A KR 1020170099113A KR 20170099113 A KR20170099113 A KR 20170099113A KR 102155246 B1 KR102155246 B1 KR 102155246B1
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- hwangchil tree
- composition
- metal salt
- tree extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 241000392544 Dendropanax morbifer Species 0.000 title description 3
- 239000002082 metal nanoparticle Substances 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 65
- 239000002105 nanoparticle Substances 0.000 claims abstract description 56
- 230000002087 whitening effect Effects 0.000 claims abstract description 40
- 230000009759 skin aging Effects 0.000 claims abstract description 33
- 239000002537 cosmetic Substances 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 230000002265 prevention Effects 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 208000012641 Pigmentation disease Diseases 0.000 claims abstract description 11
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 26
- 229910052737 gold Inorganic materials 0.000 claims description 26
- 239000010931 gold Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 206010040865 Skin hyperpigmentation Diseases 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 206010014970 Ephelides Diseases 0.000 claims description 3
- 208000003351 Melanosis Diseases 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 208000000069 hyperpigmentation Diseases 0.000 claims description 2
- 230000003810 hyperpigmentation Effects 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 abstract description 65
- 239000002184 metal Substances 0.000 abstract description 65
- 150000003839 salts Chemical class 0.000 abstract description 59
- 230000000694 effects Effects 0.000 abstract description 51
- 102000003425 Tyrosinase Human genes 0.000 abstract description 32
- 108060008724 Tyrosinase Proteins 0.000 abstract description 32
- 230000002401 inhibitory effect Effects 0.000 abstract description 26
- 230000003078 antioxidant effect Effects 0.000 abstract description 13
- 230000008099 melanin synthesis Effects 0.000 abstract description 12
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 61
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 40
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 32
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 32
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 21
- 229960000271 arbutin Drugs 0.000 description 20
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 20
- 239000013641 positive control Substances 0.000 description 17
- 238000002835 absorbance Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- -1 tetrachlorogold (III) Chemical compound 0.000 description 13
- 229960005070 ascorbic acid Drugs 0.000 description 12
- 235000010323 ascorbic acid Nutrition 0.000 description 11
- 239000011668 ascorbic acid Substances 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 7
- 230000002292 Radical scavenging effect Effects 0.000 description 7
- 229930002330 retinoic acid Natural products 0.000 description 7
- 230000002000 scavenging effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 229910017745 AgNP Inorganic materials 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229960001727 tretinoin Drugs 0.000 description 6
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 238000011278 co-treatment Methods 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000378 calcium silicate Substances 0.000 description 3
- 229910052918 calcium silicate Inorganic materials 0.000 description 3
- 235000012241 calcium silicate Nutrition 0.000 description 3
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 description 3
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 101710134784 Agnoprotein Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- XUEHVOLRMXNRKQ-KHMAMNHCSA-N alpha-cubebene Chemical compound CC(C)[C@@H]([C@H]12)CC[C@@H](C)[C@]32[C@@H]1C(C)=CC3 XUEHVOLRMXNRKQ-KHMAMNHCSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- YOVSPTNQHMDJAG-QLFBSQMISA-N β-eudesmene Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(=C)C)CC[C@]21C YOVSPTNQHMDJAG-QLFBSQMISA-N 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- GAIBLDCXCZKKJE-QRYCCKSOSA-N (-)-Germacrene D Natural products C(C)(C)[C@H]1/C=C/C(=C)CC/C=C(/C)\CC1 GAIBLDCXCZKKJE-QRYCCKSOSA-N 0.000 description 1
- RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- KSXPPAGQQYHJFU-UHFFFAOYSA-N Dendropanoxid Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2C1(O1)CCC1C2(C)C KSXPPAGQQYHJFU-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- GAIBLDCXCZKKJE-YZJXYJLZSA-N Germacren D Chemical compound CC(C)C/1CC\C(C)=C\CCC(=C)\C=C\1 GAIBLDCXCZKKJE-YZJXYJLZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910003771 Gold(I) chloride Inorganic materials 0.000 description 1
- 241001245789 Goodea atripinnis Species 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- QMAYBMKBYCGXDH-RRFJBIMHSA-N alpha-Muurolene Natural products C1CC(C)=C[C@@H]2[C@H](C(C)C)CC=C(C)[C@H]21 QMAYBMKBYCGXDH-RRFJBIMHSA-N 0.000 description 1
- QMAYBMKBYCGXDH-UHFFFAOYSA-N alpha-amorphene Natural products C1CC(C)=CC2C(C(C)C)CC=C(C)C21 QMAYBMKBYCGXDH-UHFFFAOYSA-N 0.000 description 1
- QMAYBMKBYCGXDH-ZNMIVQPWSA-N alpha-muurolene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CC=C(C)[C@H]21 QMAYBMKBYCGXDH-ZNMIVQPWSA-N 0.000 description 1
- OZQAPQSEYFAMCY-UHFFFAOYSA-N alpha-selinene Natural products C1CC=C(C)C2CC(C(=C)C)CCC21C OZQAPQSEYFAMCY-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- YOVSPTNQHMDJAG-UHFFFAOYSA-N beta-helmiscapene Natural products C1CCC(=C)C2CC(C(=C)C)CCC21C YOVSPTNQHMDJAG-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- IEICDHBPEPUHOB-UHFFFAOYSA-N ent-beta-selinene Natural products C1CCC(=C)C2CC(C(C)C)CCC21C IEICDHBPEPUHOB-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- OJIGFVZZEVQUNV-UHFFFAOYSA-N germacrene D Natural products CC(C)C1CCC=C(/C)CCC(=C)C=C1 OJIGFVZZEVQUNV-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- GAIBLDCXCZKKJE-UHFFFAOYSA-N isogermacrene D Natural products CC(C)C1CCC(C)=CCCC(=C)C=C1 GAIBLDCXCZKKJE-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 황칠나무 추출물-금속염 나노입자 복합체를 포함하는 피부상태 개선용 조성물에 관한 것으로, 구체적으로 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는 피부 미백용 또는 피부 노화 방지용 화장료 조성물, 피부 외용제, 의약외품 조성물, 약학적 조성물 및 피부 미백 또는 피부 노화 방지 방법에 관한 것이다.
본 발명에 따른 황칠나무 추출물-금속염 나노입자 복합체는 항산화 효과, 티로시나아제 활성 저해 효과 및 멜라닌 생성 억제 효과가 우수하며, 나아가 세포에 대하여 독성을 나타내지 않으므로, 피부 미백, 피부 노화, 피부 색소 침착 등의 방지, 개선 또는 치료에 유용하고 안전하게 활용될 수 있다.The present invention relates to a composition for improving skin condition comprising a hwangchil tree extract-metal salt nanoparticle complex, and specifically, for skin whitening comprising a hwangchil tree extract and a metal salt-containing metal salt nanoparticle complex as an active ingredient Or it relates to a cosmetic composition for preventing skin aging, an external preparation for the skin, a quasi-drug composition, a pharmaceutical composition, and a method for whitening or preventing skin aging.
Hwangchil tree extract-metal salt nanoparticle complex according to the present invention has excellent antioxidant effect, tyrosinase activity inhibitory effect, and melanin production inhibitory effect, and does not show toxicity to cells, so skin whitening, skin aging, skin pigmentation, etc. It can be useful and safely used in the prevention, improvement or treatment of
Description
본 발명은 황칠나무 추출물-금속염 나노입자 복합체를 포함하는 피부상태 개선용 조성물에 관한 것으로, 구체적으로 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는 피부 미백용 또는 피부 노화 방지용 화장료 조성물, 피부 외용제, 의약외품 조성물, 약학적 조성물 및 피부 미백 또는 피부 노화 방지 방법에 관한 것이다.The present invention relates to a composition for improving skin condition comprising a hwangchil tree extract-metal salt nanoparticle complex, and specifically, for skin whitening comprising a hwangchil tree extract and a metal salt-containing metal salt nanoparticle complex as an active ingredient Or it relates to a cosmetic composition for preventing skin aging, an external preparation for the skin, a quasi-drug composition, a pharmaceutical composition, and a method for whitening or preventing skin aging.
사람의 피부색은 피부 내 멜라닌(melanin)의 농도와 분포에 따라 유전적으로 결정되나, 태양 자외선이나 피로, 스트레스 등의 환경적 또는 생리적 조건에 의해서도 영향을 받는다. 멜라닌 생성에 대한 화학적 작용은 현재까지 여러 논문 등을 통해 많이 보고되고 있으며, 전구물질로서 티로신(tyrosine)이 티로시나아제(tyrosinase)에 의해 디히드록시페닐알라닌(dihydroxyphenylalanine; DOPA)으로 전환되고, 그 후 도파퀴논(dopaquinone)이라는 물질 등을 거쳐 최종적으로 멜라닌으로 전환된다고 알려져 있다. 이렇게 합성된 멜라닌은 피부색을 짙게 만드는데, 건강 또는 미용상의 요구로 인해 멜라닌 합성을 억제하여 피부색을 밝게 하려는 피부 미백 방법에 관한 연구가 활발히 진행 중이며, 관련하여 수박 내피 추출물을 포함하는 피부 미백 화장료 조성물(한국 등록특허공보 제10-1325464호), 마시멜로, 카렌듈라, 성모초 등의 식물추출물을 함유하는 피부 상태 개선용 조성물(한국 공개특허공보 제 공개번호 10-2015-0112103호) 등이 개발된 바 있다.Human skin color is genetically determined according to the concentration and distribution of melanin in the skin, but is also affected by environmental or physiological conditions such as solar ultraviolet rays, fatigue, and stress. The chemical action of melanin production has been reported in many papers so far, and tyrosine as a precursor is converted to dihydroxyphenylalanine (DOPA) by tyrosinase, and then It is known that it is finally converted to melanin through a substance called dopaquinone. The melanin synthesized in this way darkens the skin color, and research on a skin whitening method to brighten the skin color by inhibiting melanin synthesis due to health or beauty needs is actively underway, and in relation to it, a skin whitening cosmetic composition containing a watermelon endothelial extract ( Korean Patent Publication No. 10-1325464), a composition for improving skin condition containing plant extracts such as marshmallow, calendula, and St. Mary's (Korean Laid-Open Patent Publication No. 10-2015-0112103) has been developed. .
아울러, 일반적으로 알려진 미백 성분으로는 코지산(Kojic acid) 또는 알부틴(Arbutin) 등과 같은 타이로시나아제(tyrosinase)의 활성을 억제하는 물질, 비타민 C(L-Ascorbic acid) 또는 이들의 유도체와 각종 식물 추출물이 있다. 이들은 멜라닌 색소의 합성을 저해함으로써, 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착증의 개선이 가능하다. 그러나 피부 적용 시, 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적인 효과를 기대할 수 없는 문제점이 있었다.In addition, commonly known whitening ingredients include substances that inhibit the activity of tyrosinase, such as kojic acid or arbutin, vitamin C (L-Ascorbic acid) or derivatives thereof, and various There are plant extracts. By inhibiting the synthesis of melanin pigments, they can not only realize skin whitening by brightening skin tone, but also improve skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones or genetics. However, when applied to the skin, there is a problem in that the amount of use is limited due to safety issues such as irritation and redness, or the effect is insignificant, so that a practical effect cannot be expected.
멜라닌 색소의 침착뿐만 아니라 피부 노화도 다양한 요인에 의해 야기되는데, 특히 몸의 대사 과정에서 만들어지는 활성산소의 라디칼(radical)이 대표적인 요인이다. 라디칼이 피부 세포에 누적되면서 피부가 얇아지고 탄력이 떨어지며, 이로 인해 주름, 피부 처짐 노화가 야기된다. 이를 방지하기 위하여, 비타민 C, 비타민 E, 비타민 A의 전구체인 베타카로틴, 및 비타민 A의 유도체인 레티노산(retinoic acid) 등과 같은 항산화 물질을 적극적으로 이용하고 있다. 이들은 건강기능식품, 화장품 등의 유효성분으로 각광받고 있는데, 특히 비타민 C는 피부 진피에서 콜라겐의 합성과 탄력을 유지하고, 멜라닌 색소가 침착되는 것을 막아 피부 미백에 중요한 역할을 한다. The deposition of melanin pigments as well as skin aging are caused by various factors. In particular, radicals of free radicals produced in the body's metabolic process are a representative factor. As radicals accumulate in the skin cells, the skin becomes thinner and less elastic, leading to wrinkles and aging of the skin. To prevent this, antioxidants such as vitamin C, vitamin E, beta-carotene, which are precursors of vitamin A, and retinoic acid, which are derivatives of vitamin A, are actively used. They are in the spotlight as active ingredients in health functional foods and cosmetics. In particular, vitamin C plays an important role in skin whitening by maintaining the synthesis and elasticity of collagen in the skin dermis and preventing melanin pigment from being deposited.
한편, 황칠나무는 산형화목 두릅나무과에 속하는 식물로서, 덴드로파녹시드(dendropanoxide) 등의 정유 성분, 사포닌, α-큐베벤(α-Cubebene), β-엘레멘(β-Elemene), β-셀리넨(β-Selinene), α-무로렌(α-Muurolene), 저마크렌 D(Germacrene D), β-시토스테롤(β-Sitosterol) 등의 다양한 생리활성 성분이 포함되어 있다고 알려져 있다. 이에 따라, 정혈작용, 간기능 개선, 항산화 작용, 경조직(뼈와 치아) 재생, 면역력 강화, 신경안정, 항균작용, 항암작용 등의 효과를 나타냄에 따라, 전통의학에서는 유용한 약재로서 사용된다. 그러나, 황칠나무의 미백 효과에 대해서는 알려진 바 없으며, 이를 이용하여 제조된 금 또는 은 나노입자의 미백 효과도 알려진 바 없었다. On the other hand, Hwangchil tree is a plant belonging to the umbel family Araliaceae, and essential oil components such as dendropanoxide, saponins, α-Cubebene, β-Elemene, β-cell It is known that various physiologically active ingredients such as linen (β-Selinene), α-Muurolene, Germacrene D, and β-Sitosterol are contained. Accordingly, it is used as a useful medicinal material in traditional medicine, as it exhibits effects such as blood purification, liver function improvement, antioxidant activity, hard tissue (bone and tooth) regeneration, immunity strengthening, nerve stabilization, antibacterial activity, and anticancer activity. However, the whitening effect of Hwangchil wood was not known, and the whitening effect of gold or silver nanoparticles prepared using it was not known.
이러한 배경하에, 본 발명자들은 피부 미백을 촉진하고 피부 노화를 방지하는 물질을 개발하고자 예의노력 연구한 결과, 황칠나무 잎 추출물을 이용하여 제조된 황칠나무 추출물-금속염 나노입자 복합체는 우수한 미백 효과뿐만 아니라 우수한 항산화 활성을 나타냄을 확인하여, 본 발명을 완성하였다.Under this background, the inventors of the present inventors have conducted a thorough study to develop a substance that promotes skin whitening and prevents skin aging. As a result, the Hwangchil tree extract-metal salt nanoparticle complex prepared using Hwangchil tree leaf extract has an excellent whitening effect as well as By confirming that it exhibits excellent antioxidant activity, the present invention was completed.
본 발명의 하나의 목적은 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는, 피부 미백용 또는 피부 노화 방지용 화장료 조성물을 제공하는 것이다.One object of the present invention is to provide a cosmetic composition for skin whitening or skin aging, comprising a hwangchil tree extract and a metal salt-containing metal salt-metal salt nanoparticle complex as an active ingredient.
본 발명의 다른 하나의 목적은 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는, 피부 미백용 또는 피부 노화 방지용 피부 외용제를 제공하는 것이다.Another object of the present invention is to provide a skin external preparation for skin whitening or skin aging prevention, comprising a hwangchil tree extract and a metal salt-containing metal salt-metal salt nanoparticle complex as an active ingredient.
본 발명의 또 다른 하나의 목적은 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는, 피부 미백용 또는 피부 노화 방지용 의약외품 조성물을 제공하는 것이다.Another object of the present invention is to provide a quasi-drug composition for skin whitening or skin aging, comprising a hwangchil tree extract and a metal salt-containing metal salt-metal salt nanoparticle complex as an active ingredient.
본 발명의 또 다른 하나의 목적은 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는, 피부 색소 침착의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin pigmentation, comprising a hwangchil tree extract and a metal salt-containing metal salt-metal salt nanoparticle complex as an active ingredient.
본 발명의 또 다른 하나의 목적은 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는 조성물을 인간을 제외한 개체에 투여하는 단계를 포함하는, 피부 미백 또는 피부 노화 방지 방법을 제공하는 것이다.Another object of the present invention is to administer a composition comprising a Hwangchil tree extract and a metal salt-containing Hwangchil tree extract-metal salt nanoparticle complex as an active ingredient to an individual other than humans, skin whitening or skin aging It is to provide a method of prevention.
상기 목적을 달성하기 위하여, 본 발명의 하나의 양태는 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는, 피부 미백용 또는 피부 노화 방지용 화장료 조성물을 제공한다.In order to achieve the above object, one aspect of the present invention provides a cosmetic composition for skin whitening or skin aging, comprising a hwangchil tree extract and a metal salt-containing hwangchil tree extract-metal salt nanoparticle complex as an active ingredient.
본 발명에서는, 황칠나무 추출물을 사용하여 제조한 황칠나무 추출물-금속염 나노입자 복합체는 항산화 효과, 티로시나아제 활성 저해 효과 및 멜라닌 생성 억제 효과가 우수하며, 나아가 세포에 대하여 독성을 나타내지 않음을 확인하였다.In the present invention, it was confirmed that the Hwangchil tree extract-metal salt nanoparticle complex prepared using Hwangchil tree extract has excellent antioxidant effect, tyrosinase activity inhibitory effect, and melanin production inhibitory effect, and further does not show toxicity to cells. .
본 발명의 용어, "황칠나무"(Dendropanax morbifera)는 산형화목 두릅나무과에 속하는 식물을 의미한다. 황칠나무는 심신을 편하게 하고 각종 역기를 억제하며, 남성에게는 신장 강화, 여성에게는 생리불순 치료 효과 등을 나타내며, 면역세포의 생육을 촉진하여 조기 면역체계 및 생체방어체계를 강화시킬 수 있으므로 각종 질병의 예방 및 치료에 사용되고 있다. 그러나, 상기 황칠나무 추출물을 이용하여 제조된 금속염 나노입자의 미백 효과에 대해서는 알려진 바 없었다.The term of the present invention, "Hwangchil tree" ( Dendropanax morbifera ) means a plant belonging to the umbel family Araliaceae. Hwangchil tree relaxes the mind and body and suppresses various weights, strengthens the kidneys for men, and treats menstrual irregularities to women, and promotes the growth of immune cells to strengthen the early immune system and biological defense systems. It is used for prevention and treatment. However, it was not known about the whitening effect of the metal salt nanoparticles prepared using the Hwangchil tree extract.
본 발명의 용어, "황칠나무 추출물"은 황칠나무를 용매를 이용하여 통상적인 방법으로 얻어낸 황칠나무에 속한 성분이나 물질을 의미하고, 본 발명에서 상기 황칠나무 추출물은 황칠나무 잎 추출물일 수 있다.The term "hwangchil tree extract" of the present invention refers to a component or material belonging to the hwangchil tree obtained by a conventional method using a solvent of hwangchil tree, and in the present invention, the hwangchil tree extract may be a hwangchil tree leaf extract.
또한, 본 발명에서, 상기 황칠나무 추출물은 상기 황칠나무를 추출 처리하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. 상기 황칠나무를 추출하는 방법 또는 추출 용매는 특별히 제한되지 않으며, 당해 기술 분야에서 공지된 임의의 방법 또는 용매를 사용할 수 있다.In addition, in the present invention, the Hwangchil tree extract is an extract obtained by extracting the Hwangchil tree, a dilution or concentrate of the extract, a dried product obtained by drying the extract, a preparation or purified product of the extract, or a mixture thereof. , The extract itself and all formulations that can be formed using the extract are included. The method or extraction solvent for extracting the Hwangchil tree is not particularly limited, and any method or solvent known in the art may be used.
구체적으로, 상기 추출용매는 황칠나무 추출물을 제조할 수 있는 한 특별히 이에 제한되지 않으나, 물, C1 내지 C4의 알코올 또는 이들의 혼합물을 사용할 수 있으며, 구체적으로는 에탄올, 메탄올 또는 물을 사용할 수 있고, 보다 구체적으로는 증류수를 사용할 수 있다.Specifically, the extraction solvent is not particularly limited as long as the Hwangchil tree extract can be prepared, but water, C1 to C4 alcohol or a mixture thereof may be used, specifically ethanol, methanol or water, and , More specifically, distilled water may be used.
본 발명의 용어, "금속염"은 금속염 나노입자를 제조하기 위하여 첨가하는 화합물을 의미한다. 본 발명에서, 상기 금속염은 금염 또는 은염일 수 있다. 구체적으로, 상기 금염은 테트라클로로금(III)산(HAuCl4), NaAuCl3, 또는 AuCl3일 수 있으나 이에 제한되지 않으며, 상기 은염은 AgBF4, AgCF3SO3, AgClO4, AgNO3, AgPF6 또는 Ag(CF3COO)일 수 있으나 이에 제한되지 않는다.As used herein, the term "metal salt" refers to a compound added to prepare metal salt nanoparticles. In the present invention, the metal salt may be a gold salt or a silver salt. Specifically, the gold salt may be tetrachlorogold (III) acid (HAuCl 4 ), NaAuCl 3 , or AuCl 3 , but is not limited thereto, and the silver salt is AgBF 4 , AgCF 3 SO 3 , AgClO 4 , AgNO 3 , AgPF 6 or Ag (CF 3 COO), but is not limited thereto.
본 발명에서, 상기 "금속염 나노입자"는 금속으로 이루어지고, 크기가 1 내지 100nm인 초미세 입자를 의미한다. 본 발명에서, 상기 금속염 나노입자는 금염 나노입자 또는 은염 나노입자일 수 있다.In the present invention, the "metal salt nanoparticles" are made of metal and mean ultrafine particles having a size of 1 to 100 nm. In the present invention, the metal salt nanoparticles may be gold salt nanoparticles or silver salt nanoparticles.
본 발명의 용어, "황칠나무 추출물-금속염 나노입자 복합체"는 황칠나무 추출물과 금속염 나노입자가 결합되거나 연결되어, 금속염 나노입자에 황칠나무 추출물이 포함된 형태를 의미한다. 본 발명의 황칠나무 추출물-금속염 나노입자 복합체는 황칠나무 추출물의 생리활성 물질을 포함하고 있으므로, 화학적인 방법으로 제조된 일반의 금속염 나노입자에 비하여 더 우수한 피부 미백 또는 피부 노화 방지 효과를 나타낼 수 있다.The term "hwangchil tree extract-metal salt nanoparticle complex" of the present invention refers to a form in which the hwangchil tree extract and the metal salt nanoparticles are combined or connected to the metal salt nanoparticles. Since the Hwangchil tree extract-metal salt nanoparticle complex of the present invention contains the physiologically active substance of the Hwangchil tree extract, it may exhibit a better skin whitening or skin aging prevention effect compared to general metal salt nanoparticles prepared by a chemical method. .
본 발명의 목적상, 상기 황칠나무 추출물-금속염 나노입자 복합체는 황칠나무 추출물을 이용하여 제조된 것일 수 있다.For the purposes of the present invention, the Hwangchil tree extract-metal salt nanoparticle complex may be prepared using a Hwangchil tree extract.
또한, 본 명세서에서, 상기 황칠나무 추출물-금염 나노입자 복합체는 '금 나노입자' 또는 D-AuNPs'로 혼용되어 명명될 수 있고, 또한 상기 황칠나무 추출물-은염 나노입자 복합체는 '은 나노입자' 또는 'D-AgNPs'로 혼용되어 명명될 수 있다.In addition, in the present specification, the Hwangchil tree extract-gold salt nanoparticle complex may be referred to as'gold nanoparticles' or D-AuNPs', and the Hwangchil tree extract-silver salt nanoparticle complex is'silver nanoparticles' Alternatively, it may be referred to as'D-AgNPs'.
본 발명의 용어, "피부 미백"은 피부 톤을 밝게 하고, 자외선, 호르몬 또는 유전 등 다양한 요인에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 의미한다.As used herein, the term "skin whitening" means to brighten skin tone and improve skin hyperpigmentation such as spots and freckles caused by various factors such as ultraviolet rays, hormones, or genetics.
본 발명의 용어, "피부 노화"는 피부의 탄력 감소, 윤기 감소, 주름 생성, 재생력 약화 또는 심한 건조 등의 증상이 나타나는 것을 의미하며, "피부 노화 방지"는 피부 노화 등의 증상을 억제 또는 저해하거나, 이미 나타난 피부 노화의 증상을 완화하는 것을 의미한다.The term "skin aging" as used herein refers to symptoms such as decreased skin elasticity, reduced gloss, wrinkle formation, weakened regeneration, or severe dryness, and "skin aging prevention" inhibits or inhibits symptoms such as skin aging. Or it means relieving the symptoms of skin aging that have already appeared.
본 발명의 구체적인 일 실시예에서는, 황칠나무 잎 추출물을 이용하여 제조된 금 또는 은 나노입자는 우수한 항산화 활성을 갖고(도 1), 티로시나아제 활성 저해 효과(도 2 및 3) 및 멜라닌 생성 저해 효과를 나타내며(도 4), 나아가 세포에 독성을 나타내지 않고(도 5), H2O2에 의해 감소된 세포의 라디칼을 소거함으로써 세포의 생존율을 증가시킬 수 있음을 확인하였다(도 6). 또한, 상기와 같은 금 또는 은 나노입자의 효과는 양성 대조군인 아스코르브산 또는 알부틴과 유사하거나 더 우수함을 확인하였다. 이는, 상기 황칠나무 추출물-금속염 나노입자 복합체를 포함하는 본 발명의 화장료 조성물은 피부 미백 또는 피부 노화 방지 용도로 유용하게 사용될 수 있음을 시사하는 것이다.In a specific embodiment of the present invention, gold or silver nanoparticles prepared using the Hwangchil tree leaf extract have excellent antioxidant activity (Figure 1), tyrosinase activity inhibitory effect (Figures 2 and 3), and melanin production inhibition It was confirmed that the effect was shown (FIG. 4), and further, it was not toxic to the cells (FIG. 5), and the survival rate of the cells could be increased by scavenging the radicals of the cells reduced by H 2 O 2 (FIG. 6). In addition, it was confirmed that the effect of the gold or silver nanoparticles as described above was similar to or better than that of ascorbic acid or arbutin, which are positive controls. This suggests that the cosmetic composition of the present invention comprising the Hwangchil tree extract-metal salt nanoparticle complex can be usefully used for skin whitening or skin aging prevention.
본 발명의 화장료 조성물은 상기 황칠나무 추출물-금속염 나노입자 복합체를 총 중량 대비 0.0001 내지 80 중량%, 구체적으로 0.0005 내지 70 중량%, 더욱 구체적으로 0.001 내지 60 중량% 포함할 수 있다. 상기 함량이 0.0001 중량% 미만이면 본래 목적하는 효과를 충분하게 달성할 수 없어 바람직하지 못하며, 80 중량%를 초과하면 증가하는 함량만큼 뚜렷한 효과의 증대가 기대되지 않아 비경제적이며, 화장료 조성물의 안전성에 문제를 발생시킬 수 있다.The cosmetic composition of the present invention may contain 0.0001 to 80% by weight, specifically 0.0005 to 70% by weight, and more specifically 0.001 to 60% by weight, based on the total weight of the Hwangchil tree extract-metal salt nanoparticle complex. If the content is less than 0.0001% by weight, it is not preferable because the original intended effect cannot be sufficiently achieved, and if it exceeds 80% by weight, it is uneconomical because no obvious increase in the effect is expected as much as the increasing content. It can cause problems.
또한, 본 발명의 화장료 조성물은 피부에 사용하는 것으로서, 유연화장수(영양유액), 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 팩, 피부접착용 패취, 피부접착용 겔, 파우더, 연고, 서스펜션, 에멀젼, 스프레이 또는 미용액 등의 통상의 화장료 형태로 제조될 수 있으나, 이에 제한되는 것은 아니다. 또한, 상기 화장료 조성물은 화장품, 비누, 세제 및 섬유 등의 피부에 접촉하는 피부접촉물질로 제조할 수도 있다. In addition, the cosmetic composition of the present invention is used for the skin, softening lotion (nutrition emulsion), astringent lotion, nutritional lotion, nutritional cream, massage cream, essence, pack, patch for skin adhesion, gel for skin adhesion, powder, ointment , Suspension, emulsion, spray, or may be prepared in the form of a cosmetic composition, such as a cosmetic solution, but is not limited thereto. In addition, the cosmetic composition may be made of skin-contacting materials such as cosmetics, soaps, detergents, and fibers.
또한, 상기 화장료 조성물은 필요에 따라 일반 피부화장료에 배합되는 보통의 성분, 예를 들면, 유분, 물, 계면활성제, 보습제, 저급알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등의 화장품학적으로 허용 가능한 담체를 추가로 포함할 수 있으나, 이에 제한되는 것은 아니다. In addition, the cosmetic composition is a cosmetic composition such as ordinary ingredients, such as oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, etc., which are mixed in general skin cosmetics as needed. It may further include an acceptable carrier, but is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 화장료 조성물의 제형에 따라 다양하다.The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation of the cosmetic composition.
구체적으로, 본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화 아연 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2종 이상 혼합되어 사용될 수 있다.Specifically, when the formulation of the present invention is an ointment, paste, cream or gel, as a carrier component, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, Zinc oxide or the like may be used, but is not limited thereto. These may be used alone or in combination of two or more.
또한, 본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 등이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로하드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2종 이상 혼합되어 사용될 수 있다.In addition, when the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be used as a carrier component. In particular, in the case of a spray, additional chlorofluoro It may include a propellant such as lohardrocarbon, propane/butane or dimethyl ether, but is not limited thereto. These may be used alone or in combination of two or more.
또한, 본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제 등이 이용될 수 있으며, 예를 들어 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일 등이 이용될 수 있고, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2종 이상 혼합되어 사용될 수 있다.In addition, when the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent may be used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, Benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, and the like can be used, and in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or sour. Non-fat fatty acid esters may be used, but are not limited thereto. These may be used alone or in combination of two or more.
또한, 본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타하이드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2종 이상 혼합되어 사용될 수 있다.In addition, when the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used, but is not limited thereto. These may be used alone or in combination of two or more.
또한, 본 발명의 제형이 비누인 경우에는, 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알코올, 식물성 유, 글리세롤, 당 등이 이용될 수 있으나, 이에 제한되는 것은 아니다. 이들은 단독으로 사용되거나 2종 이상 혼합되어 사용될 수 있다.In addition, when the formulation of the present invention is a soap, as a carrier component, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolyzate, isethionate, a lanolin derivative, an aliphatic alcohol, vegetable oil, glycerol, sugar, etc. May be used, but is not limited thereto. These may be used alone or in combination of two or more.
본 발명의 다른 하나의 양태는 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는, 피부 미백 또는 피부 노화 방지용 피부 외용제를 제공한다.Another aspect of the present invention provides a skin external preparation for skin whitening or skin aging prevention, comprising a hwangchil tree extract and a metal salt-containing metal salt nanoparticle complex as an active ingredient.
이때, 상기 용어 "황칠나무 추출물", "금속염", "황칠나무 추출물-금속염 나노입자 복합체", "피부 미백", "피부 노화" 및 "방지"에 대한 설명은 상술한 바와 같다.At this time, the terms "Hwangchil tree extract", "metal salt", "Hwangchil tree extract-metal salt nanoparticle complex", "skin whitening", "skin aging" and "prevention" are as described above.
본 발명의 용어, "피부 외용제"는 일반적으로 피부 외용에 사용하는 물질 전반을 포함하는 포괄하는 개념으로, 피부 외용제 제형의 비제한적인 예로는 경고제(plasters), 로션제(lotions), 리니멘트제(liniments), 액제(liquid and solution), 에어로솔제(aerosol), 엑스제(extracts), 연고제(ointments), 유동엑스제(fluid extracts), 유제(emulsion), 현탁제(suspesions), 캅셀제(capsules), 크림제(creams), 연질, 경질 젤라틴 캅셀, 첩부제 또는 서방화제제 등이 있으나, 이에 제한되지 않는다.The term "external skin preparation" of the present invention is a concept encompassing all substances generally used for external application of the skin, and non-limiting examples of the external preparation for skin include plasters, lotions, and liniment Liniments, liquid and solutions, aerosols, extracts, ointments, fluid extracts, emulsions, suspensions, capsules ( capsules), creams, soft, hard gelatin capsules, patches or sustained release agents, etc., but are not limited thereto.
본 발명에 따른 피부 외용제는 상용되는 무기 또는 유기의 담체, 부형제 및 희석제를 가하여 고체, 반고체 또는 액상의 형태로 제제화된 비경구 투여제일 수 있다. 상기 비경구 투여를 위한 제제로는 점적제, 연고, 로션, 겔, 크림, 패취, 스프레이, 현탁제 및 유제로 이루어진 군에서 선택되는 경피 투여형 제형일 수 있으나, 이에 제한되지 않는다.The external preparation for skin according to the present invention may be a parenteral administration formulation formulated in a solid, semi-solid or liquid form by adding a commercially available inorganic or organic carrier, excipient, and diluent. The formulation for parenteral administration may be a transdermal dosage form selected from the group consisting of drops, ointments, lotions, gels, creams, patches, sprays, suspensions, and emulsions, but is not limited thereto.
상기 외용제에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 또는 광물유를 들 수 있다. Carriers, excipients, and diluents that may be included in the external preparation include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil.
각 제형에 의한 피부 외용제 조성물에 있어서, 본 발명의 황칠나무 추출물-금속염 나노입자 복합체 이외의 다른 성분들을 기타 피부 외용제의 제형 또는 사용 목적 등에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 이 경우 다른 원료와 동시에 적용할 경우 상승효과가 일어날 수 있다.In the composition for external application for skin according to each formulation, components other than the Hwangchil tree extract-metal salt nanoparticle complex of the present invention can be appropriately selected and blended by those skilled in the art without difficulty depending on the formulation or purpose of use of other skin external preparations. Synergistic effects may occur when applied simultaneously with other raw materials.
본 발명의 구체적인 일 실시예에서는, 황칠나무 잎 추출물을 이용하여 제조된 금 또는 은 나노입자는 우수한 항산화 활성을 갖고(도 1), 티로시나아제 활성 저해 효과(도 2 및 3) 및 멜라닌 생성 저해 효과를 나타내며(도 4), 나아가 세포에 독성을 나타내지 않고(도 5), H2O2에 의해 감소된 세포의 라디칼을 소거함으로써 세포의 생존율을 증가시킬 수 있음을 확인하였다(도 6). 또한, 상기와 같은 금 또는 은 나노입자의 효과는 양성 대조군인 아스코르브산 또는 알부틴과 유사하거나 더 우수함을 확인하였다. 이는, 상기 황칠나무 추출물-금속염 나노입자 복합체를 포함하는 본 발명의 피부 외용제는 피부 미백 또는 피부 노화 방지 용도로 유용하게 사용될 수 있음을 시사하는 것이다.In a specific embodiment of the present invention, gold or silver nanoparticles prepared using the Hwangchil tree leaf extract have excellent antioxidant activity (Figure 1), tyrosinase activity inhibitory effect (Figures 2 and 3), and melanin production inhibition It was confirmed that the effect was shown (FIG. 4), and further, it was not toxic to the cells (FIG. 5), and the survival rate of the cells could be increased by scavenging the radicals of the cells reduced by H 2 O 2 (FIG. 6). In addition, it was confirmed that the effect of the gold or silver nanoparticles as described above was similar to or better than that of ascorbic acid or arbutin, which are positive controls. This suggests that the external preparation for skin of the present invention comprising the Hwangchil tree extract-metal salt nanoparticle complex can be usefully used for skin whitening or skin aging prevention.
본 발명의 또 다른 하나의 양태는 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는, 피부 미백 또는 피부 노화 방지용 의약외품 조성물을 제공한다.Another aspect of the present invention provides a quasi-drug composition for skin whitening or skin aging prevention, comprising a hwangchil tree extract and a metal salt-containing metal salt-metal salt nanoparticle complex as an active ingredient.
이때, 상기 용어 "황칠나무 추출물", "금속염", "황칠나무 추출물-금속염 나노입자 복합체", "피부 미백", "피부 노화" 및 "방지"에 대한 설명은 상술한 바와 같다.At this time, the terms "Hwangchil tree extract", "metal salt", "Hwangchil tree extract-metal salt nanoparticle complex", "skin whitening", "skin aging" and "prevention" are as described above.
본 발명의 용어, "의약외품"은 사람이나 동물의 질병을 진단, 치료, 개선, 경감, 처치 또는 예방할 목적으로 사용되는 물품들 중 의약품보다 작용이 경미한 물품들을 의미하는 것으로, 예를 들어 약사법에 따르면 의약외품이란 의약품의 용도로 사용되는 물품을 제외한 것으로, 사람/동물의 질병 치료나 예방에 쓰이는 제품, 인체에 대한 작용이 경미하거나 직접 작용하지 않는 제품 등이 포함된다.The term "quasi-drug" of the present invention refers to items that are less effective than pharmaceuticals among items used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases of humans or animals, for example, according to the Pharmaceutical Affairs Act. Quasi-drugs exclude items used for pharmaceutical purposes, and include products used to treat or prevent diseases of humans/animals, and products that have mild or no direct action on the human body.
본 발명의 의약외품 조성물은 바디 클렌저, 폼, 비누, 마스크, 연고제, 크림, 로션, 에센스 및 스프레이로 이루어진 군에서 선택되는 하나 이상으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The quasi-drug composition of the present invention may be prepared as one or more selected from the group consisting of a body cleanser, foam, soap, mask, ointment, cream, lotion, essence, and spray, but is not limited thereto.
본 발명에 따른 황칠나무 추출물-금속염 나노입자 복합체를 의약외품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 의약외품 또는 의약외품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합량은 사용 목적에 따라 적합하게 결정될 수 있다.When the Hwangchil tree extract-metal salt nanoparticle complex according to the present invention is used as a quasi-drug additive, the composition may be added as it is or may be used with other quasi-drugs or quasi-drug components, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use.
본 발명의 구체적인 일 실시예에서는, 황칠나무 잎 추출물을 이용하여 제조된 금 또는 은 나노입자는 우수한 항산화 활성을 갖고(도 1), 티로시나아제 활성 저해 효과(도 2 및 3) 및 멜라닌 생성 저해 효과를 나타내며(도 4), 나아가 세포에 독성을 나타내지 않고(도 5), H2O2에 의해 감소된 세포의 라디칼을 소거함으로써 세포의 생존율을 증가시킬 수 있음을 확인하였다(도 6). 또한, 상기와 같은 금 또는 은 나노입자의 효과는 양성 대조군인 아스코르브산 또는 알부틴과 유사하거나 더 우수함을 확인하였다. 이는, 상기 황칠나무 추출물-금속염 나노입자 복합체를 포함하는 본 발명의 의약외품은 피부 미백 또는 피부 노화 방지 용도로 유용하게 사용될 수 있음을 시사하는 것이다.In a specific embodiment of the present invention, gold or silver nanoparticles prepared using the Hwangchil tree leaf extract have excellent antioxidant activity (Figure 1), tyrosinase activity inhibitory effect (Figures 2 and 3), and melanin production inhibition It was confirmed that the effect was shown (FIG. 4), and further, it was not toxic to the cells (FIG. 5), and the survival rate of the cells could be increased by scavenging the radicals of the cells reduced by H 2 O 2 (FIG. 6). In addition, it was confirmed that the effect of the gold or silver nanoparticles as described above was similar to or better than that of ascorbic acid or arbutin, which are positive controls. This suggests that the quasi-drug product of the present invention containing the Hwangchil tree extract-metal salt nanoparticle complex can be usefully used for skin whitening or skin aging prevention.
본 발명의 또 다른 하나의 양태는 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는, 피부 색소 침착의 예방 또는 치료용 약학적 조성물을 제공한다.Another aspect of the present invention provides a pharmaceutical composition for preventing or treating skin pigmentation, comprising a hwangchil tree extract and a metal salt-containing metal salt-metal salt nanoparticle complex as an active ingredient.
이때, 상기 용어 "황칠나무 추출물", "금속염" 및 "황칠나무 추출물-금속염 나노입자 복합체"에 대한 설명은 상술한 바와 같다.In this case, the description of the terms "Hwangchil tree extract", "metal salt" and "Hwangchil tree extract-metal salt nanoparticle complex" is as described above.
본 발명의 용어, "피부 색소 침착"은 피부, 손발톱, 구강이나 비강을 둘러싸고 있는 점막 등에 멜라닌 증가에 의해 발생한 과다 색소 침착 반(macule)을 의미하며, 과색소침착이라고도 한다.As used herein, the term "skin pigmentation" refers to a hyperpigmented macule caused by an increase in melanin on the skin, nails, or the mucous membrane surrounding the oral cavity or nasal cavity, and is also referred to as hyperpigmentation.
본 발명의 용어, "예방"은 본 발명의 약학적 조성물의 투여에 의해 피부 색소 침착을 억제시키거나 또는 지연시키는 모든 행위를 의미한다.The term "prevention" of the present invention means any action of inhibiting or delaying skin pigmentation by administration of the pharmaceutical composition of the present invention.
본 발명의 용어, "치료"는 본 발명의 약학적 조성물의 투여에 의해 피부 색소 침착이 호전되거나 이롭게 변경되는 모든 행위를 의미한다.The term "treatment" of the present invention means any action in which skin pigmentation is improved or beneficially altered by administration of the pharmaceutical composition of the present invention.
본 발명의 구체적인 일 실시예에서는, 황칠나무 잎 추출물을 이용하여 제조된 금 또는 은 나노입자는 우수한 항산화 활성을 갖고(도 1), 티로시나아제 활성 저해 효과(도 2 및 3) 및 멜라닌 생성 저해 효과를 나타내며(도 4), 나아가 세포에 독성을 나타내지 않고(도 5), H2O2에 의해 감소된 세포의 라디칼을 소거함으로써 세포의 생존율을 증가시킬 수 있음을 확인하였다(도 6). 또한, 상기와 같은 금 또는 은 나노입자의 효과는 양성 대조군인 아스코르브산 또는 알부틴과 유사하거나 더 우수함을 확인하였다. 이는, 상기 황칠나무 추출물-금속염 나노입자 복합체를 포함하는 본 발명의 약학적 조성물은 피부 색소 침착의 예방 또는 개선 용도로 유용하게 사용될 수 있음을 시사하는 것이다.In a specific embodiment of the present invention, gold or silver nanoparticles prepared using the Hwangchil tree leaf extract have excellent antioxidant activity (Figure 1), tyrosinase activity inhibitory effect (Figures 2 and 3), and melanin production inhibition It was confirmed that the effect was shown (FIG. 4), and further, it was not toxic to the cells (FIG. 5), and the survival rate of the cells could be increased by scavenging the radicals of the cells reduced by H 2 O 2 (FIG. 6). In addition, it was confirmed that the effect of the gold or silver nanoparticles as described above was similar to or better than that of ascorbic acid or arbutin, which are positive controls. This suggests that the pharmaceutical composition of the present invention containing the Hwangchil tree extract-metal salt nanoparticle complex can be usefully used for preventing or improving skin pigmentation.
본 발명의 약학적 조성물은 피부 색소 침착을 예방하고 치료하기 위한 통상의 방법에 따라 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 에어로졸, 멸균 주사용액 등의 형태로 제형화가 가능하다.The pharmaceutical composition of the present invention is in the form of tablets, pills, powders, granules, capsules, suspensions, liquids, emulsions, syrups, aerosols, sterile injectable solutions, etc. according to conventional methods for preventing and treating skin pigmentation. It can be formulated as.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제도 사용될 수 있다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 포함되며, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 사용될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. Can be. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may be used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, syrups, etc., and various excipients, such as humectants, sweeteners, fragrances, and preservatives, in addition to water and liquid paraffin, which are commonly used simple diluents. Can be used.
비경구투여를 위한 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등을 포함할 수 있다. 비수성용제와 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일 등과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.Formulations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations, suppositories, and the like. As the non-aqueous solvent and the suspension solvent, vegetable oils such as propylene glycol, polyethylene glycol, olive oil, and injectable esters such as ethyl oleate may be used.
또한, 본 발명의 약학적 조성물은 담체, 부형제 또는 희석제를 추가로 포함할 수 있다. 담체, 부형제 또는 희석제로는 락토즈, 텍스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오즈, 메틸 셀루로오즈, 하이드록시 프로필 메틸 셀룰로오즈, 미정질 셀룰로오즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 플로필히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 이산화규소 등의 광물유 등이 사용될 수 있다.In addition, the pharmaceutical composition of the present invention may further include a carrier, excipient or diluent. Carriers, excipients or diluents include lactose, textrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, hydroxy Mineral oils such as propyl methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, flophilhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and silicon dioxide can be used. have.
본 발명에 따른 약학적 조성물의 구체적인 투여량은 제제화 방법, 환자의 상태 및 체중, 환자의 성별, 연령, 질병의 정도, 약물형태, 투여경로 및 기간, 배설 속도, 반응 감응성 등과 같은 요인들에 따라 당업자에 의해 다양하게 선택될 수 있으며, 투여량 및 횟수는 어떠한 면에서든 본 발명의 범위를 제한하는 것은 아니다.The specific dosage of the pharmaceutical composition according to the present invention depends on factors such as formulation method, patient's condition and weight, patient's sex, age, degree of disease, drug type, route and duration of administration, excretion rate, response sensitivity, etc. It can be selected in various ways by those skilled in the art, and the dosage and frequency do not limit the scope of the present invention in any way.
본 발명의 약학적 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로를 통해 투여될 수 있다. 투여의 모든 방식은 예상될 수 있으며, 예를 들어 경구, 정맥, 근육 또는 피하 주사에 의해 투여될 수 있다.The pharmaceutical composition of the present invention can be administered to mammals such as mice, mice, livestock, and humans through various routes. All modes of administration can be expected and can be administered, for example by oral, intravenous, intramuscular or subcutaneous injection.
본 발명의 또 다른 하나의 양태는 황칠나무 추출물 및 금속염을 포함하는 황칠나무 추출물-금속염 나노입자 복합체를 유효성분으로 포함하는 조성물을 인간을 제외한 개체에 투여하는 단계를 포함하는, 피부 미백 또는 피부 노화 방지 방법을 제공한다.Another aspect of the present invention is a skin whitening or skin aging comprising administering a composition comprising a hwangchil tree extract and a metal salt-containing metal salt nanoparticle complex as an active ingredient to an individual other than a human. Provides a method of prevention.
이때, 상기 용어 "황칠나무 추출물", "금속염", "황칠나무 추출물-금속염 나노입자 복합체", "피부 미백", "피부 노화" 및 "방지"에 대한 설명은 상술한 바와 같다..At this time, the descriptions of the terms "Hwangchil tree extract", "metal salt", "Hwangchil tree extract-metal salt nanoparticle complex", "skin whitening", "skin aging" and "prevention" are as described above.
본 발명의 용어, "투여"는 어떠한 적절한 방법으로 환자에게 본 발명의 조성물 도입하는 것을 의미한다.The term "administration" of the present invention means introducing the composition of the present invention to a patient by any suitable method.
본 발명의 용어, "개체"는 피부 색소의 침착 또는 피부 노화가 발병하였거나 발병할 수 있는 인간을 포함한 쥐, 생쥐, 가축 등의 모든 동물을 의미한다. 구체적으로, 인간을 포함한 포유동물일 수 있다.As used herein, the term "individual" refers to all animals such as rats, mice, livestock, including humans, which have or may develop skin pigmentation or skin aging. Specifically, it may be a mammal including a human.
상기 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. 복강 내 투여, 정맥 내 투여, 근육 내 투여, 피하 투여, 피내 투여, 경구 투여, 국소 투여, 비 내 투여될 수 있으나, 이에 제한되지는 않는다. 본 발명의 조성물이 피부 미백 또는 피부 노화 등의 개선에 효과가 있는 특성상, 상기 조성물의 투여 경로는 피부에 도포하여 투여될 수 있다.The administration route of the composition may be administered through any general route as long as it can reach the target tissue. Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, but are not limited thereto. Due to the nature of the composition of the present invention that is effective in improving skin whitening or skin aging, the route of administration of the composition may be applied to the skin and administered.
본 발명의 조성물을 매일 투여 또는 간헐적으로 투여해도 좋고, 1일당 투여 횟수는 1회 또는 2 내지 3회로 나누어 투여하는 것이 가능하다. 또한, 본 발명의 조성물은 피부 미백 또는 피부 노화를 위하여 단독으로, 또는 다른 약물 치료와 병용하여 사용할 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다.The composition of the present invention may be administered daily or intermittently, and the number of administrations per day may be administered once or divided into 2 to 3 times. In addition, the composition of the present invention may be used alone or in combination with other drug treatments for skin whitening or skin aging. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and can be easily determined by a person skilled in the art.
본 발명의 구체적인 일 실시예에서는, 황칠나무 잎 추출물을 이용하여 제조된 금 또는 은 나노입자는 우수한 항산화 활성을 갖고(도 1), 티로시나아제 활성 저해 효과(도 2 및 3) 및 멜라닌 생성 저해 효과를 나타내며(도 4), 나아가 세포에 독성을 나타내지 않고(도 5), H2O2에 의해 감소된 세포의 라디칼을 소거함으로써 세포의 생존율을 증가시킬 수 있음을 확인하였다(도 6). 또한, 상기와 같은 금 또는 은 나노입자의 효과는 양성 대조군인 아스코르브산 또는 알부틴과 유사하거나 더 우수함을 확인하였다. 이는, 상기 황칠나무 추출물-금속염 나노입자 복합체를 포함하는 조성물을 이용하는 본 발명의 피부 미백 또는 피부 노화 방지 방법은 목적하는 효과를 우수한 정도로 달성할 수 있음을 시사하는 것이다.In a specific embodiment of the present invention, gold or silver nanoparticles prepared using the Hwangchil tree leaf extract have excellent antioxidant activity (Figure 1), tyrosinase activity inhibitory effect (Figures 2 and 3), and melanin production inhibition It was confirmed that the effect was shown (FIG. 4), and further, it was not toxic to the cells (FIG. 5), and the survival rate of the cells could be increased by scavenging the radicals of the cells reduced by H 2 O 2 (FIG. 6). In addition, it was confirmed that the effect of the gold or silver nanoparticles as described above was similar to or better than that of ascorbic acid or arbutin, which are positive controls. This suggests that the method for whitening or preventing skin aging of the present invention using a composition containing the Hwangchil tree extract-metal salt nanoparticle complex can achieve a desired effect to an excellent degree.
본 발명에 따른 황칠나무 추출물-금속염 나노입자 복합체는 항산화 효과, 티로시나아제 활성 저해 효과 및 멜라닌 생성 억제 효과가 우수하며, 나아가 세포에 대하여 독성을 나타내지 않으므로, 피부 미백, 피부 노화, 피부 색소 침착 등의 방지, 개선 또는 치료에 유용하고 안전하게 활용될 수 있다.Hwangchil tree extract-metal salt nanoparticle complex according to the present invention has excellent antioxidant effect, tyrosinase activity inhibitory effect, and melanin production inhibitory effect, and does not show toxicity to cells, so skin whitening, skin aging, skin pigmentation, etc. It can be useful and safely used in the prevention, improvement or treatment of
도 1은 본 발명의 일 실시예에 따라 황칠나무 잎 추출물을 이용하여 제조한, 금 나노입자(D-AuNPs) 또는 은 나노입자(D-AgNPs)의 DPPH 라디칼 소거 활성을 보여주는 그래프이다. Vit. C(vitamin C)는 양성 대조군인 아스코르브산(ascorbic acid)을 의미한다.
도 2는 상기 D-AuNPs 또는 D-AgNPs의 시험관 내 버섯 티로시나아제(mushroom tyrosinase) 활성 저해율을 보여주는 그래프이다. DE는 황칠나무 잎 추출물, Arbutin은 양성 대조군인 알부틴을 의미한다.
도 3은 상기 D-AuNPs에 의해 감소된 세포의 티로시나아제 활성을 보여주는 그래프이다. α-MSH(α-Melanocyte-stimulating hormone)는 멜라닌 형성 자극 호르몬, DE는 황칠나무 잎 추출물, Arbutin은 양성 대조군인 알부틴을 의미한다. ###는 티로시나아제 활성을 비교하기 위한 음성 대조군을 의미하고, *, ** 및 ***는 상기 음성 대조군에 대하여 통계적 유의성이 p <0.05, p <0.01 및 p <0.001인 것을 의미한다.
도 4는 상기 D-AuNPs에 의해 감소된 세포의 멜라닌 양을 보여주는 그래프이다. α-MSH는 멜라닌 형성 자극 호르몬, DE는 황칠나무 잎 추출물, Arbutin은 양성 대조군인 알부틴을 의미한다. ##는 티로시나아제 활성을 비교하기 위한 음성 대조군을 의미하고, *, ** 및 ***는 상기 음성 대조군에 대하여 통계적 유의성이 p <0.05, p <0.01 및 p <0.001인 것을 의미한다.
도 5는 상기 D-AuNPs의 세포 독성을 보여주는 그래프로서, D-AuNPs 처리 시 HDF(Human dermal fibroblast) 또는 B16(murine melanoma B16BL6) 세포의 생존율을 보여준다. DE는 황칠나무 잎 추출물, RA(Retinoic acid)는 양성 대조군인 레티논산을 의미한다. A 내지 C는 HDF, 및 D 내지 F는 B16 세포에 관한 것이고; A 및 D는 D-AuNPs를 24시간 처리, B 및 E는 D-AuNPs를 48시간 처리, 및 C 및 F는 D-AuNPs를 72시간 처리한 결과에 관한 것이다.
도 6은 상기 D-AuNPs의 세포 라디칼 소거 활성을 보여주는 그래프로서, 라디칼에 의해 손상된 세포에 대한 세포 생존율 증가 활성을 보여준다. Pre-treatment는 H2O2의 전처리, Co-treatment는 H2O2의 공동처리, 및 Post-treatment는 H2O2의 후처리 조건을 의미한다. A.A는 양성 대조군인 아스코르브산, DE는 황칠나무 잎 추출물을 의미한다. ###는 티로시나아제 활성을 비교하기 위한 음성 대조군을 의미하고, *, ** 및 ***는 상기 음성 대조군에 대하여 통계적 유의성이 p <0.05, p <0.01 및 p <0.001인 것을 의미한다.1 is a graph showing the DPPH radical scavenging activity of gold nanoparticles (D-AuNPs) or silver nanoparticles (D-AgNPs) prepared using a hwangchil tree leaf extract according to an embodiment of the present invention. Vit. C (vitamin C) refers to ascorbic acid, which is a positive control.
Figure 2 is a graph showing the inhibition rate of mushroom tyrosinase activity in vitro of the D-AuNPs or D-AgNPs. DE stands for Hwangchil tree leaf extract, and Arbutin stands for arbutin, a positive control.
3 is a graph showing the tyrosinase activity of cells reduced by the D-AuNPs. α-MSH (α-Melanocyte-stimulating hormone) refers to melanin formation stimulating hormone, DE refers to Hwangchil tree leaf extract, and Arbutin refers to arbutin, a positive control. ### means a negative control for comparing tyrosinase activity, and *, ** and *** mean that statistical significance is p <0.05, p <0.01, and p <0.001 with respect to the negative control. .
4 is a graph showing the amount of melanin in cells reduced by the D-AuNPs. α-MSH stands for melanin formation stimulating hormone, DE stands for Hwangchil tree leaf extract, and Arbutin stands for arbutin, a positive control. ## means a negative control for comparing tyrosinase activity, and *, ** and *** mean that statistical significance is p <0.05, p <0.01, and p <0.001 with respect to the negative control.
Figure 5 is a graph showing the cytotoxicity of the D-AuNPs, showing the survival rate of HDF (Human dermal fibroblast) or B16 (murine melanoma B16BL6) cells when D-AuNPs are treated. DE refers to Hwangchil tree leaf extract, and RA (Retinoic acid) refers to retinoic acid, a positive control. A-C relates to HDF, and D-F relates to B16 cells; A and D refer to the results of treatment with D-AuNPs for 24 hours, B and E for 48 hours treatment with D-AuNPs, and C and F refer to the results of treatment with D-AuNPs for 72 hours.
6 is a graph showing the cell radical scavenging activity of the D-AuNPs, showing the activity of increasing cell viability against cells damaged by the radical. Pre-treatment refers to pretreatment of H 2 O 2 , Co-treatment refers to co-treatment of H 2 O 2 , and Post-treatment refers to post-treatment conditions of H 2 O 2 . AA refers to ascorbic acid as a positive control, and DE refers to Hwangchil tree leaf extract. ### means a negative control for comparing tyrosinase activity, and *, ** and *** mean that statistical significance is p <0.05, p <0.01 and p <0.001 with respect to the negative control. .
이하, 하기 실시예를 통하여 본 발명을 더욱 상세하게 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail through the following examples. These examples are for illustrative purposes only and are not to be construed as limiting the scope of the present invention by these examples.
제조예Manufacturing example 1. 황칠나무 추출물을 이용한 금 또는 은 나노입자의 제조 방법 1. Method for producing gold or silver nanoparticles using Hwangchil tree extract
제조예Manufacturing example 1-1. 황칠나무 추출물의 제조방법 1-1. Method for producing Hwangchil tree extract
황칠나무(Dendropanax Morbifera) 추출물을 이용한 친환경적인 방법으로 금 또는 은 나노입자를 제조하기 위하여, 먼저 황칠나무 추출물을 제조하였다. Dendropanax Morbifera ) In order to prepare gold or silver nanoparticles by an eco-friendly method using an extract, Hwangchil tree extract was first prepared.
구체적으로, 황칠나무의 잎을 탈이온수로 세척하고, 작게 자른 다음 건조시켰다. 건조한 상기 잎 5 g을 증류수를 포함하는 1 ℓ의 비커에 넣고 30분간 가열하였다. 실온에서 식힌 이후 5,000rpm으로 10분간 원심분리하였고, 거름종이로 여과함으로써 황칠나무 잎 추출물을 수득하였다.Specifically, the leaves of the Hwangchil tree were washed with deionized water, cut into small pieces, and then dried. 5 g of the dried leaves were placed in a 1 liter beaker containing distilled water and heated for 30 minutes. After cooling at room temperature, it was centrifuged at 5,000 rpm for 10 minutes, and filtered through filter paper to obtain a hwangchil tree leaf extract.
제조예Manufacturing example 1-2. 금 나노입자(D- 1-2. Gold nanoparticles (D- AuNPsAuNPs )의 제조방법) Manufacturing method
황칠나무 추출물을 이용한 친환경적인 방법으로 금 나노입자(D-AuNPs)를 제조하기 위하여, 다음과 같은 방법을 수행하였다.In order to prepare gold nanoparticles (D-AuNPs) by an eco-friendly method using Hwangchil tree extract, the following method was performed.
구체적으로, 상기 제조예 1-1에서 제조한 황칠나무 잎 추출물 5 ㎖를 45 ㎖의 탈이온수와 혼합하고, 최종 농도가 1 mM이 되도록 하여 테트라클로로금(Ⅲ)산(HAuCl4·3H2O) 수용액을 상기 용액에 첨가하였다. 상기 용액을 80℃에서 1시간 동안 인큐베이션한 다음, 반응혼합액의 색 변화를 관찰함으로써 금 나노입자의 생성 여부를 확인하였다. 이후, 16,000 rpm으로 20분간 원심분리하여 금 나노입자를 회수하였으며, 이를 탈이온수로 여러 번 세척한 후 건조하여 사용하였다.Specifically, 5 ml of the Hwangchil tree leaf extract prepared in Preparation Example 1-1 was mixed with 45 ml of deionized water, and the final concentration was 1 mM, so that tetrachlorogold(III) acid (HAuCl 4· 3H 2 O ) An aqueous solution was added to the solution. After incubating the solution at 80° C. for 1 hour, it was confirmed whether gold nanoparticles were generated by observing the color change of the reaction mixture. Thereafter, the gold nanoparticles were collected by centrifugation at 16,000 rpm for 20 minutes, washed several times with deionized water, and dried and used.
제조예Manufacturing example 1-3. 은 나노입자(D- 1-3. Silver nanoparticles (D- AgNPsAgNPs )의 제조방법) Manufacturing method
친환경적인 방법으로 은 나노입자(D-AgNPs)를 제조하기 위하여, 다음과 같은 방법을 수행하였다.In order to prepare silver nanoparticles (D-AgNPs) in an eco-friendly way, the following method was performed.
구체적으로, 상기 제조예 1-1에서 제조한 황칠나무 잎 추출물 5 ㎖를 45 ㎖의 탈이온수와 혼합하고, 최종 농도가 1 mM이 되도록 하여 질산은(AgNO3) 수용액을 상기 용액에 첨가하였다. 상기 용액을 80℃에서 1시간 인큐베이션한 다음, 반응혼합액의 색 변화를 관찰함으로써 은 나노입자의 생성 여부를 확인하였다. 이후, 16,000 rpm으로 20분간 원심분리하여 은 나노입자를 회수하였으며, 이를 탈이온수로 여러 번 세척한 후 건조하여 사용하였다.Specifically, 5 ml of the hwangchil tree leaf extract prepared in Preparation Example 1-1 was mixed with 45 ml of deionized water, and the final concentration was 1 mM, and an aqueous silver nitrate (AgNO 3 ) solution was added to the solution. After incubating the solution at 80° C. for 1 hour, it was confirmed whether silver nanoparticles were generated by observing the color change of the reaction mixture. Thereafter, the silver nanoparticles were recovered by centrifugation at 16,000 rpm for 20 minutes, washed several times with deionized water, and dried and used.
실시예Example 1. 황칠나무 추출물을 이용하여 제조된 금 또는 은 나노입자(D- 1. Gold or silver nanoparticles (D- AuNPsAuNPs 또는 D-AgNPs)의 항산화 활성 확인 Or check the antioxidant activity of D-AgNPs)
상기 제조예 1을 통해 제조한 금 또는 은 나노입자(D-AuNPs 또는 D-AgNPs)의 피부상태 개선 효과를 확인하기 위하여, 먼저 항산화 이들의 활성을 확인하였다.In order to confirm the effect of improving the skin condition of the gold or silver nanoparticles (D-AuNPs or D-AgNPs) prepared through Preparation Example 1, the antioxidant activity was first confirmed.
구체적으로, DPPH 라디칼 소거 활성을 확인하였다. DPPH의 0.1 mM 메탄올 용액 180 ㎕를 10 내지 500 ㎍/㎖의 서로 다른 농도를 갖는 D-AuNPs 또는 D-AgNP 용액 20 ㎕에 첨가하였고, 30분 후 UV-Vis 분광 광도계를 이용하여 517 nm에서 흡광도 값을 측정하였으며, 하기 수학식 1을 통해 DPPH 라디칼 소거 활성을 계산하였다. 아스코르브산(ascorbic acid)은 양성 대조군으로 사용하였다. Specifically, DPPH radical scavenging activity was confirmed. 180 µl of 0.1 mM methanol solution of DPPH was added to 20 µl of D-AuNPs or D-AgNP solutions having different concentrations of 10 to 500 µg/ml, and absorbance at 517 nm using a UV-Vis spectrophotometer after 30 minutes The value was measured, and DPPH radical scavenging activity was calculated through
[수학식 1][Equation 1]
[(DPPH의 흡광도-샘플의 흡광도-대조군의 흡광도)/DPPH의 흡광도]×100[(Absorbance of DPPH-absorbance of sample-absorbance of control)/absorbance of DPPH]×100
이때, 상기 샘플의 흡광도는 나노입자가 포함된 DPPH 용액의 흡광도이고, 대조군의 흡광도는 D-AuNPs 또는 D-AgNPs 용액의 흡광도이다. At this time, the absorbance of the sample is the absorbance of the DPPH solution containing nanoparticles, and the absorbance of the control is the absorbance of the D-AuNPs or D-AgNPs solution.
그 결과, 도 1에서 볼 수 있듯이, D-AuNP 또는 D-AgNP는 용량 의존적으로 DPPH 라디칼 소거 활성을 나타냄을 확인하였으며, 항산화제로 사용되는 아스코르브산의 DPPH 소거 활성과 많은 차이를 나타내지 않음을 확인하였다.As a result, as can be seen in Figure 1, it was confirmed that D-AuNP or D-AgNP exhibited DPPH radical scavenging activity in a dose-dependent manner, and it was confirmed that it did not show much difference from the DPPH scavenging activity of ascorbic acid used as an antioxidant. .
실시예Example 2. D- 2. D- AuNPsAuNPs 또는 D- Or D- AgNPs의AgNPs 시험관 내 티로시나아제 활성 저해 효과 확인 Confirmation of tyrosinase activity inhibitory effect in vitro
상기 제조예 1을 통해 제조한 D-AuNPs 또는 D-AgNPs의 피부상태 개선 효과를 확인하기 위하여, 시험관 내(in vitro) 티로시나아제(tyrosinase) 활성 저해 효과를 확인하였다.In order to confirm the effect of improving the skin condition of D-AuNPs or D-AgNPs prepared in Preparation Example 1, the effect of inhibiting tyrosinase activity in vitro was confirmed.
구체적으로, 버섯 티로시나아제(mushroom tyrosinase)에 대한 활성 저해 효과를 확인하였다. 2 mM의 L-DOPA 0.05 ㎖를 인산완충용액(50 mM, pH 6.8)에 녹인 후 D-AuNP, D-AgNP 또는 황칠나무 잎 추출물(DE) 시료 0.05 ㎖를 96-웰 마이크로 플레이트에 넣고 버섯 티로시나아제(200 U/㎖) 0.05 ㎖를 혼합하였다. 혼합물을 37℃에서 30분 동안 인큐베이션하였으며, ELISA 판독기(Bio-Tek Instrument, Vermont, USA)를 이용하여 492 nm에서 광학 밀도를 측정하였고, 하기 수학식 2를 통해 티로시나아제 활성 저해율을 계산하였다. 알부틴(arbutin)은 양성 대조군으로 사용하였다. Specifically, it was confirmed that the inhibitory effect on the activity of mushroom tyrosinase (mushroom tyrosinase). After dissolving 0.05 ml of 2 mM L-DOPA in a phosphate buffer solution (50 mM, pH 6.8), 0.05 ml of D-AuNP, D-AgNP or Hwangchil tree leaf extract (DE) sample was put into a 96-well microplate and mushroom tiro. 0.05 ml of synase (200 U/ml) were mixed. The mixture was incubated at 37° C. for 30 minutes, and the optical density was measured at 492 nm using an ELISA reader (Bio-Tek Instrument, Vermont, USA), and the tyrosinase activity inhibition rate was calculated through
[수학식 2][Equation 2]
티로시나아제 활성 저해율(%) = [(A-B)/(C-D)]×100Tyrosinase activity inhibition rate (%) = [(A-B)/(C-D)]×100
이때, A는 시험 시료(D-AuNP, D-AgNP 또는 DE) 및 버섯 티로시나아제가 포함된 반응 혼합물의 흡광도, B는 시험 시료는 있으나 버섯 티로시나아제가 없는 반응 혼합물의 흡광도, C는 버섯 티로시나아제는 있으나 시험 시료가 없는 반응 혼합물의 흡광도, 및 D는 L-DOPA만 포함되어 있는 웰의 흡광도이다.Here, A is the absorbance of the reaction mixture containing the test sample (D-AuNP, D-AgNP or DE) and mushroom tyrosinase, B is the absorbance of the reaction mixture with the test sample but no mushroom tyrosinase, C is the mushroom The absorbance of the reaction mixture with tyrosinase but no test sample, and D is the absorbance of a well containing only L-DOPA.
한편, 본 발명에 따른 모든 실험은 독립적으로 3번 수행하였고, 모든 데이터는 평균 ± 표준 편차 (S.D.)로 표시하였다. 시료(D-AuNP, D-AgNP 또는 양성 대조군)를 처리한 그룹의 평균값과 이들을 처리하지 않은 그룹의 평균값을 비교하였고, 이들의 통계적 유의성은 스튜던트 t-검정(Student's t-test)을 사용하여 확인하였다.On the other hand, all experiments according to the present invention were independently performed three times, and all data were expressed as mean ± standard deviation (S.D.). The average value of the group treated with the sample (D-AuNP, D-AgNP or positive control) was compared with the average value of the group without treatment, and their statistical significance was confirmed using Student's t-test. I did.
상기 결과를 통해, D-AuNP 또는 D-AgNP는 알부틴과 유사한 시험관 내 티로시나아제 저해 활성을 나타내므로, 우수한 피부 미백 효과를 나타낼 것임을 알 수 있었다.Through the above results, it was found that D-AuNP or D-AgNP exhibited an in vitro tyrosinase inhibitory activity similar to arbutin, and thus would exhibit an excellent skin whitening effect.
실시예 3. D- AuNPs의 피부 미백 효과 확인 Example 3. Confirmation of skin whitening effect of D- AuNPs
실시예Example 3-1. 세포의 티로시나아제 활성 저해 효과 확인 3-1. Confirmation of the inhibitory effect of cell tyrosinase activity
상기 제조예 1을 통해 제조한 D-AuNPs의 피부상태 개선 효과를 확인하기 위하여, 세포의 티로시나아제에 대한 활성 저해 효과를 확인하였다.In order to confirm the effect of improving the skin condition of D-AuNPs prepared in Preparation Example 1, the inhibitory effect on the activity of cells against tyrosinase was confirmed.
구체적으로, 마우스 멜라닌 형성 세포인 B16(murine melanoma B16BL6) 세포를 4 × 105 세포/웰의 밀도로 100 mm 플레이트에 배양하였고, 100 nM α-MSH(α-Melanocyte-stimulating hormone)를 처리한 상태로 24시간 동안 배양하였다. 이후, 상기 세포를 1-100 ㎍/㎖ 농도의 D-AuNPs를 처리하여 24시간 동안 배양하였으며, 이후 배지를 제거하고 1% Triton X-100을 포함하는 인산 완충액(pH 6.9)으로 용해하였다. 상기 용해물을 -80℃에서 15분 동안 동결-해동시킨 후 실온에서 10분간 유지하였다. 이후, 12,000g에서 15분간 원심 분리한 후, 기질 용액(50 mM 인산완충용액(pH 7.1)에 포함된 15 mM L-DOPA)을 90 ㎕의 용해물 상등액에 넣고 1시간 동안 37℃에서 배양하였으며, ELISA 판독기를 사용하여 흡광도를 475 nm에서 측정하였다.Specifically, mouse melanoma-forming cells, B16 (murine melanoma B16BL6) cells, were cultured in a 100 mm plate at a density of 4 × 10 5 cells/well, and treated with 100 nM α-MSH (α-Melanocyte-stimulating hormone). Incubated for 24 hours. Thereafter, the cells were treated with D-AuNPs at a concentration of 1-100 μg/ml and cultured for 24 hours. After that, the medium was removed and lysed in a phosphate buffer (pH 6.9) containing 1% Triton X-100. The lysate was freeze-thaw at -80°C for 15 minutes and then kept at room temperature for 10 minutes. Thereafter, after centrifugation at 12,000 g for 15 minutes, a substrate solution (15 mM L-DOPA contained in 50 mM phosphate buffer solution (pH 7.1)) was added to 90 μl of the lysate supernatant and incubated at 37° C. for 1 hour. , Absorbance was measured at 475 nm using an ELISA reader.
그 결과, 도 3에서 볼 수 있듯이, D-AuNPs는 알부틴 또는 황칠나무 잎 추출물보다 우수한 세포의 티로시나아제 저해 활성을 나타냄을 확인하였다. 구체적으로, 100 ㎍/㎖ 농도의 알부틴을 처리하는 경우 B16 세포의 티로시나아제 활성은 약 80%이고, 25 ㎍/㎖ 농도의 황칠나무 잎 추출물을 처리하는 경우 B16 세포의 티로시나아제 활성은 약 70%인 것에 비하여, 25 ㎍/㎖ 농도의 D-AuNPs를 처리하는 경우 B16 세포의 티로시나아제 활성은 약 40%인 것을 확인하였다.As a result, as can be seen in Figure 3, it was confirmed that D-AuNPs showed superior cellular tyrosinase inhibitory activity than arbutin or hwangchil tree leaf extract. Specifically, 100 μg/ml In the case of treatment with a concentration of arbutin, the tyrosinase activity of B16 cells is about 80%, 25 μg/ml When the concentration of Hwangchil tree leaf extract is treated, the tyrosinase activity of B16 cells is about 70%, compared to 25 ㎍/㎖ Concentration When treated with D-AuNPs, it was confirmed that the tyrosinase activity of B16 cells was about 40%.
상기 결과를 통해, D-AuNP는 낮은 농도에서도 알부틴 또는 황칠나무 잎 추출물보다 현저히 우수한 세포의 티로시나아제 저해 활성을 나타내므로, 우수한 피부 미백 효과를 나타낼 것임을 알 수 있었다.Through the above results, it was found that D-AuNP exhibited remarkably superior cellular tyrosinase inhibitory activity than arbutin or hwangchil tree leaf extract even at a low concentration, and thus it was found that it would exhibit excellent skin whitening effect.
실시예Example 3-2. 세포의 멜라닌 생성 저해 효과 확인 3-2. Confirmation of cell melanogenesis inhibitory effect
상기 제조예 1을 통해 제조한 D-AuNPs의 피부상태 개선 효과를 확인하기 위하여, 세포의 멜라닌 생성 저해 효과를 확인하였다.In order to confirm the effect of improving the skin condition of D-AuNPs prepared in Preparation Example 1, the effect of inhibiting the production of melanin in cells was confirmed.
구체적으로, 마우스 멜라닌 형성 세포인 B16 세포를 4 × 105 세포/웰의 밀도로 100 mm 플레이트에 배양하였고, 100 nM α-MSH를 처리한 상태로 24시간 동안 배양하였다. 이후, 상기 세포를 1 내지 100 ㎍/㎖ 농도의 D-AuNPs를 처리하여 24시간 동안 배양하였으며, 배지를 제거하고 세포를 수득한 후 10% DMSO가 함유 된 1 N NaOH 500 ㎕에 용해하여 80℃에서 1시간 동안 보관하였다. 이후, ELISA 판독기를 이용하여 475 nm에서 흡광도를 측정함으로써 생성된 멜라닌 양을 확인하였다. 이때, 합성 멜라닌(0 내지 100 ㎍/㎖)에 대한 표준 곡선과 비교하여 멜라닌 양을 확인하였으며, 생성된 멜라닌 양은 시료가 처리되지 않은 음성 대조군에 대한 백분율로 나타내었다.Specifically, mouse melanin-forming cells, B16 cells, were cultured in a 100 mm plate at a density of 4 × 10 5 cells/well, and cultured for 24 hours while being treated with 100 nM α-MSH. Thereafter, the cells were treated with D-AuNPs at a concentration of 1 to 100 μg/ml and cultured for 24 hours. After removing the medium and obtaining the cells, the cells were dissolved in 500 μl of 1 N NaOH containing 10% DMSO and dissolved at 80° C. Stored at for 1 hour. Thereafter, the amount of melanin produced was confirmed by measuring the absorbance at 475 nm using an ELISA reader. At this time, the amount of melanin was confirmed by comparing it with a standard curve for synthetic melanin (0 to 100 µg/ml), and the amount of melanin generated was expressed as a percentage of the negative control without sample treatment.
그 결과, 도 4에서 볼 수 있듯이, D-AuNPs는 알부틴 또는 황칠나무 잎 추출물보다 우수한 멜라닌 생성 저해 활성을 나타냄을 확인하였다. 구체적으로, 100 ㎍/㎖ 농도의 알부틴을 처리하는 경우 B16 세포의 멜라닌 양은 약 80%인 것에 비하여, 25 ㎍/㎖ 농도의 D-AuNPs를 처리하는 경우 생성된 B16 세포의 멜라닌 양은 약 70%인 것을 확인하였다.As a result, as can be seen in Figure 4, it was confirmed that D-AuNPs exhibited superior melanin production inhibitory activity than arbutin or hwangchil tree leaf extract. Specifically, 100 μg/ml In the case of treatment with a concentration of arbutin, the amount of melanin in B16 cells is about 80%, compared to 25 ㎍/㎖ Concentration When processing D-AuNPs, it was confirmed that the amount of melanin in the generated B16 cells was about 70%.
상기 결과를 통해, D-AuNP는 낮은 농도에서도 알부틴보다 우수한 멜라닌 생성 저해 활성을 나타내는 등 우수한 피부 미백 효과를 나타냄을 알 수 있었다.Through the above results, it was found that D-AuNP exhibited excellent skin whitening effect, such as exhibiting superior melanogenesis inhibitory activity than arbutin even at low concentrations.
실시예 4. D- AuNPs의 피부 안전성 확인 Example 4. Confirmation of skin safety of D- AuNPs
실시예Example 4-1. 세포 독성 확인 4-1. Cytotoxicity check
상기 제조예 1을 통해 제조한 D-AuNPs의 피부 안전성을 확인하기 위하여, 세포에 대한 독성을 확인하였다.In order to confirm the skin safety of D-AuNPs prepared through Preparation Example 1, toxicity to cells was confirmed.
구체적으로, 세포 독성은 MTT 어세이를 통한 세포 생존율을 측정하여 확인하였다. 인간 피부 섬유아세포(Human dermal fibroblast; HDF) 및 마우스 멜라닌 형성 세포인 B16 세포를 96-웰 플레이트에 1×105 세포/웰의 밀도로 접종하고 24시간 동안 배양하였으며, 90%의 세포 밀도를 가질 때 1 내지 100 ㎍/㎖의 D-AuNP 또는 RA(Retinoic acid, 양성 대조군)를 처리하여 24, 48 및 72시간 동안 배양하였다. 이후, MTT 분석 용액(PBS 중 5 mg/㎖) 10 ㎕를 각 웰에 첨가하고 37℃에서 3 시간 동안 배양한 다음 최종적으로 100 ㎕ DMSO를 첨가하여 형성된 포르마잔(formazan) 결정을 용해시켜 그의 흡광도를 ELISA 판독기로 570 nm에서 측정하였다.Specifically, cytotoxicity was confirmed by measuring cell viability through the MTT assay. Human dermal fibroblast (HDF) and mouse melanin-forming cells, B16 cells, were inoculated in a 96-well plate at a density of 1×10 5 cells/well and cultured for 24 hours, and had a cell density of 90%. At this time, 1 to 100 μg/ml of D-AuNP or RA (Retinoic acid, positive control) was treated and cultured for 24, 48 and 72 hours. Thereafter, 10 μl of MTT assay solution (5 mg/ml in PBS) was added to each well, incubated at 37° C. for 3 hours, and finally, 100 μl DMSO was added to dissolve the formed formazan crystals, and its absorbance Was measured at 570 nm with an ELISA reader.
그 결과, 도 5에서 볼 수 있듯이, 인간 및 마우스 세포 모두에 대하여, D-AuNP는 100 ㎍/㎖의 고농도에서 72시간 동안 배양하여도 세포에 독성을 나타내지 않으며, 오히려 세포 생존율을 증가시키는 것을 확인하였다.As a result, as can be seen in Figure 5, for both human and mouse cells, D-AuNP does not show toxicity to cells even when cultured for 72 hours at a high concentration of 100 μg/ml, but rather increases cell viability. I did.
상기 결과를 통해, D-AuNP는 세포 독성을 나타내지 않으므로, 화장료 조성물의 유효성분으로서 유용하고 안전하게 사용될 수 있음을 알 수 있었다.Through the above results, since D-AuNP does not show cytotoxicity, it was found that it can be useful and safely used as an active ingredient of a cosmetic composition.
실시예Example 4-2. 손상된 세포의 라디칼 소거 활성 확인 4-2. Confirmation of radical scavenging activity of damaged cells
상기 제조예 1을 통해 제조한 D-AuNPs의 피부 안전성을 확인하기 위하여, H2O2에 의해 손상된 세포에 대한 라디칼 소거 활성, 즉 세포의 재생 능력을 확인하였다.In order to confirm the skin safety of D-AuNPs prepared in Preparation Example 1, the radical scavenging activity against cells damaged by H 2 O 2 , that is, the regeneration ability of cells was confirmed.
구체적으로, 인간 피부 섬유아세포를 96웰 플레이트에 1 × 105 세포/웰의 밀도로 접종하고 37℃에서 24시간 동안 배양하였다. 세포를 황칠나무 잎 추출물 또는 5, 10 및 25 ㎍/㎖의 D-AuNP로 처리하였으며, 이때 H2O2는 각각 전처리(Pre-treatment), 공동처리(Co-treatment) 및 후처리(Post-treatment)하였다. 전처리 조건으로는 세포에 시료(황칠나무 잎 추출물 또는 D-AuNPs)를 처리한 후 H2O2를 1시간 동안 처리하였고, 공동처리 조건으로는 H2O2 및 시료를 동시에 1시간 동안 처리하였고, 후처리 조건으로는 H2O2를 1시간 동안 처리하고 이를 헹구어낸 후 시료를 처리하였다. 이후, 실시예 4-1에 따른 방법으로 MTT 어세이를 수행하였다. 양성 대조군으로는 아스코르브산(100 ㎍/㎖)을 사용하였다.Specifically, human skin fibroblasts were inoculated into a 96-well plate at a density of 1 × 10 5 cells/well and cultured at 37° C. for 24 hours. Cells were treated with Hwangchil tree leaf extract or 5, 10, and 25 ㎍/㎖ of D-AuNP, where H 2 O 2 was each pre-treatment, co-treatment, and post-treatment. treatment). As a pretreatment condition, cells were treated with a sample (Hwangchil tree leaf extract or D-AuNPs), and then H 2 O 2 was treated for 1 hour, and as a co-treatment condition, H 2 O 2 and the sample were simultaneously treated for 1 hour. As a post-treatment condition, H 2 O 2 was treated for 1 hour, rinsed, and then the sample was treated. Thereafter, the MTT assay was performed by the method according to Example 4-1. Ascorbic acid (100 μg/ml) was used as a positive control.
그 결과, 도 6에서 볼 수 있듯이, D-AuNPs는 H2O2 처리에 의해 감소된 세포의 라디칼을 소거하여 세포의 생존율을 증가시킬 수 있음을 확인하였다. 구체적으로, 전처리, 공동처리 및 후처리의 모든 조건에서, H2O2만 처리한 음성 대조군의 경우에는 세포의 생존율이 약 80%인 것에 비하여, D-AuNPs를 처리하는 경우에는 세포의 생존율이 약 90%로서 양성 대조군인 아스코르브산을 처리한 세포와 유사한 정도임을 확인하였다.As a result, as can be seen in Figure 6, it was confirmed that D-AuNPs can increase the survival rate of cells by scavenging the radicals of the cells reduced by the H 2 O 2 treatment. Specifically, under all conditions of pre-treatment, co-treatment, and post-treatment, in the case of the negative control group treated with only H 2 O 2 , the viability of cells is about 80%, whereas in the case of D-AuNPs, the viability of cells is It was confirmed that it was about 90%, which was similar to the cells treated with ascorbic acid as a positive control.
상기 결과를 통해, D-AuNP는 H2O2에 의해 손상된 세포의 라디칼을 소거하여 이들을 회복 및 재생시킬 수 있으므로, 라디칼에 의한 피부 노화 등에 대하여 우수한 개선 효과를 나타낼 것임을 알 수 있었다.Through the above results, it was found that D-AuNP can recover and regenerate radicals in cells damaged by H 2 O 2 , and thus, it was found that it would exhibit excellent improvement effects on skin aging caused by radicals.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예 및 실험예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will be able to understand that the present invention can be implemented in other specific forms without changing the technical spirit or essential features thereof. In this regard, the examples and experimental examples described above are illustrative in all respects and should be understood as non-limiting. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the claims to be described later rather than the above detailed description and equivalent concepts are included in the scope of the present invention.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170099113A KR102155246B1 (en) | 2017-08-04 | 2017-08-04 | Composition for improving skin conditions comprising Dendropanax Morbifera extracts-metal nanoparticles complex |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170099113A KR102155246B1 (en) | 2017-08-04 | 2017-08-04 | Composition for improving skin conditions comprising Dendropanax Morbifera extracts-metal nanoparticles complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190015683A KR20190015683A (en) | 2019-02-14 |
| KR102155246B1 true KR102155246B1 (en) | 2020-09-11 |
Family
ID=65366213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170099113A Active KR102155246B1 (en) | 2017-08-04 | 2017-08-04 | Composition for improving skin conditions comprising Dendropanax Morbifera extracts-metal nanoparticles complex |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102155246B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102426151B1 (en) * | 2020-10-23 | 2022-07-27 | 김형식 | Cosmetic composition and method for preparing the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101544176B1 (en) | 2015-03-12 | 2015-08-12 | (주)에이씨티 | Stabilizing method for skin whitening, anti-wrinkle, anti-inflammatory and anti-oxidant activity of Dendropanax Morbifera Nakai Extracts from Jeju island and cosmetic composition containing the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101176529B1 (en) * | 2009-12-31 | 2012-08-24 | 주식회사 코리아나화장품 | Cosmetic Composition Comprising the extract of Dendropanax morbifera as Active Ingredient |
| KR20130114493A (en) * | 2012-04-09 | 2013-10-17 | 주식회사 엔에스텍 | Cosmetic compositions comprising the extract of dendropanax morbiferum as an active ingredient |
-
2017
- 2017-08-04 KR KR1020170099113A patent/KR102155246B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101544176B1 (en) | 2015-03-12 | 2015-08-12 | (주)에이씨티 | Stabilizing method for skin whitening, anti-wrinkle, anti-inflammatory and anti-oxidant activity of Dendropanax Morbifera Nakai Extracts from Jeju island and cosmetic composition containing the same |
Non-Patent Citations (1)
| Title |
|---|
| Muhammad Nadeem et al., A review of the green syntheses and anti-microbial applications of gold nanoparticles, Green Chemistry Letters and Reviews, pp. 216-227 (2017.07.21.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190015683A (en) | 2019-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
| KR102022622B1 (en) | Composition for improving skin conditions comprising panax ginseng sprout extract or fraction thereof and method for improving skin conditions using the same | |
| KR100850686B1 (en) | Melanoma seed extract having skin whitening activity and cosmetic composition for whitening containing same as active ingredient | |
| JP2011195502A (en) | Fibroblast proliferation promoter, anti-ageing agent and wrinkle-ameliorating agent | |
| KR100860604B1 (en) | Cosmetic Composition Containing Strobe Pine Bark Extract | |
| KR100860605B1 (en) | Cosmetic Composition Containing Strobe Pine Bark Extract and Niacinamide | |
| KR20210134284A (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
| KR102283012B1 (en) | Whitening composition comprising an extract of Elaeagnus macrophylla or a fraction thereof as an active ingredient | |
| KR100894714B1 (en) | White Wool Extract with Skin Whitening and Antioxidant Activity | |
| KR102155246B1 (en) | Composition for improving skin conditions comprising Dendropanax Morbifera extracts-metal nanoparticles complex | |
| KR100742267B1 (en) | Seojangchae chrysanthemum extract, preparation method thereof and whitening cosmetic composition containing same as active ingredient | |
| KR102326592B1 (en) | Method to extract natural product using dry ice and composition containing extract obtained therefrom | |
| KR100602684B1 (en) | Cosmetic composition for whitening containing forage extract as an active ingredient | |
| KR101317433B1 (en) | The cosmetic composition for skin whitening comprising the mixture of extract of Hovenia dulcia, Platycodon grandiflorum, wheat bud and sage | |
| KR102183896B1 (en) | Composition for improving skin | |
| KR20170137559A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR102763933B1 (en) | Composition for improving skin condition comprising extract of Pisum sativum var. arvense (L.) Poir. | |
| KR101720712B1 (en) | Composition for improving skin comprising levistilledide A | |
| KR102262362B1 (en) | Composition for improving skin conditions comprising an extract of oriental melon stem or cucumber stem | |
| KR102152932B1 (en) | Composition for improving skin conditions comprising catechin glycoside and method for improving skin conditions using the same | |
| KR100930592B1 (en) | Skin whitening and antioxidant composition containing extracts against | |
| JP5405782B2 (en) | Ceramide production promoter and moisturizer | |
| JP5167042B2 (en) | Ceramide production promoter, moisturizer and external preparation for skin | |
| KR100760585B1 (en) | Carnation Extract with Skin Whitening and Antioxidant Activity | |
| KR20250092491A (en) | Composition for skin whitening comprising Mangifera indica L. Irwin extract as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20170804 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20181101 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20170804 Comment text: Patent Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20191128 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200728 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200907 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20200908 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20240430 Start annual number: 5 End annual number: 5 |